Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease "HUPrevent"

Recruiting

Phase 2 Results N/A

Summary of Purpose

This is a pilot study of hydroxyurea versus placebo to reduce central nervous system complications (abnormally fast blood flow to the brain, silent cerebral infarct or stroke) in young children with sickle cell disease. The investigators plan to identify children 12 to 48 months old without central nervous system complications and randomly assign 20 to treatment with hydroxyurea and 20 to treatment with placebo...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 September 2016.

1 Oct 2011 30 Jun 2011 1 Oct 2017 1 Oct 2017 1 Sep 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts